New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte's Genomic Tests in Interstitial Lung Disease and Lung CancerBusiness Wire • 10/18/22
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market AccessBusiness Wire • 09/13/22
New Data Presented at ESMO 2022 Show Veracyte's Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate CancerBusiness Wire • 09/11/22
New Data Suggest Veracyte's Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive TherapyBusiness Wire • 09/07/22
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceBusiness Wire • 09/01/22
New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell LymphomaBusiness Wire • 08/29/22
Veracyte, Inc. (VCYT) CEO Marc Stapley on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in ThyroidBusiness Wire • 07/20/22
New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte's Percepta Genomic Sequencing Classifier in Lung Cancer DiagnosisBusiness Wire • 07/13/22
Wall Street Analysts Predict a 41% Upside in Veracyte (VCYT): Here's What You Should KnowZacks Investment Research • 07/05/22
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive YearBusiness Wire • 06/27/22
New Data Show Strong Performance of Veracyte's Afirma GSC in Real-World Clinical PracticeBusiness Wire • 06/20/22
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer ProgressionBusiness Wire • 06/03/22
Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal CancerBusiness Wire • 05/31/22
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic ClassifierBusiness Wire • 05/26/22
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay's Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint InhibitorsBusiness Wire • 05/26/22